Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03455543
Other study ID # RBI.2017.002
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 26, 2018
Est. completion date July 18, 2019

Study information

Verified date July 2020
Source Regenesis Biomedical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Part A of this trial is a multi-center, prospective, double-blinded, sham-controlled, randomized clinical trial. Part A will evaluate PEMF treatment compared to sham treatment in patients with painful diabetic distal symmetric peripheral neuropathy (DSPN) when treatment is administered 30 minutes twice daily through a 120-day period (4 months). Part B is a 8-month open-label active treatment extension period designed to collect longer-term data on pain, medication use, quality of life and safety (Part B).Part B of this trial is a an extension period upon completion of Part A.


Description:

Eligible subjects will be entered into a 14-day ePRO diary run-in period to collect average baseline pain scores related to their diabetic neuropathy in the lower extremities, diary compliance, and analgesic consumption (maintenance and prn prescribed peripheral neuropathic pain medication pill counts). Subjects will collect electronic patient-reported outcome (ePRO) data each morning around the same time during the run-in period.

Subjects will return to the clinic at Baseline (Day 0) for review of eligibility, diary compliance, average baseline diabetic neuropathic pain score of ≥4 and <9, and review of stable analgesic pain consumption profile during the 14-day run-in period. Qualified subjects based on diary compliance and average pain score will be randomized 1:1 (active: sham) and will be instructed to self-treat twice daily for 120 days. Subjects will record electronic patient-reported outcome (ePRO) data following each morning treatment for 120 days. Subjects consenting to distal thigh and distal leg skin biopsies during the Screening visit will have biopsies collected and sent to the central laboratory for assessment. All subjects will have baseline assessments conducted.

Subjects will receive a telephone call at Day 7 to ensure compliance to treatment and diary completion, provide follow-up information on the biopsy sites (if applicable), complete a blinding assessment as well as be assessed for safety and concomitant medication changes.

At Month 1 subjects will return to the clinic for evaluation of safety, concomitant medication changes, review device usage and ePRO diary completion, and Patient Global Impression (PGI). Treatment satisfaction will also be assessed.

At Month 2 subjects will return to the clinic for evaluation of safety, concomitant medication changes, treatment satisfaction, review of device usage (reports will be supplied to the site) and ePRO diary completion, quality of life outcomes (WPAIQ and NeuroQoL), Patient Global Impression (PGI), and interim visit measurements of SPP.

At Month 3, subjects will return to the clinic for evaluation of safety, concomitant medication changes, review device usage (reports will be supplied to the site) and ePRO diary completion, and Patient Global Impression (PGI). Treatment satisfaction will also be assessed.

At Month 4 (end of Part A / start of Part B), subjects will return to the clinic for evaluation of safety, treatment satisfaction, review of device usage (reports will be supplied to the site), HbA1c, concomitant medication changes, weight, quality of life outcomes (WPAIQ and NeuroQoL), PGI, final measurements of SPP, NCS, QST and be assessed to determine their Toronto Clinical Neuropathy Score. Those subjects who consented and had biopsies collected at the Enrollment visit, will have their end of study biopsies during this visit and samples sent directly to the central laboratory for assessment. Subjects will return the study device and complete a blinding assessment.

Subjects that complete Part A will continue into the open-label extension period (Part B). All subjects will be reconsented if not completed at a prior visit and given an open-label active device. Subjects will record ePRO data for one week prior to the Month 6, 8, 10, and 12 visits following each morning treatment. Subjects will be reminded of the150-day (Month 5) phone call.

At Month 5, subjects will receive a telephone call to ensure compliance to treatment, and to be assessed for safety and concomitant medication changes.

At Month 6, subjects will receive a telephone call to ensure treatment compliance and collection of diary data, and to assess safety and concomitant medication changes.

At Month 7, subjects will receive a telephone call to ensure treatment compliance, and to assess safety and concomitant medication changes.

At Month 8, subjects will return to the clinic for evaluation of safety, measure QST, treatment satisfaction, review of device usage and collection of diary data, concomitant medication changes, quality of life outcomes (NeuroQoL), and PGI.

At Month 9, subjects will receive a telephone call to ensure treatment compliance, and to assess safety and concomitant medication changes.

At Month 10, subjects will receive a telephone call to ensure treatment compliance and collection of diary data, and to assess safety and concomitant medication changes.

At Month 11, subjects will receive a telephone call to ensure treatment compliance, and to assess safety and concomitant medication changes.

At Month 12 (end of open-label treatment extension), subjects will return to the clinic for evaluation of safety, weight, QST, NCS, TCNSS, PGI, treatment satisfaction, review of device usage and collection of diary data, concomitant medication changes, quality of life outcomes (NeuroQoL), and will return the study device. Subjects who consented and had biopsies collected at the 4 Month visit, will have their end of study biopsies performed during this visit.


Recruitment information / eligibility

Status Completed
Enrollment 182
Est. completion date July 18, 2019
Est. primary completion date November 14, 2018
Accepts healthy volunteers No
Gender All
Age group 22 Years to 80 Years
Eligibility Inclusion Criteria:

- Type 1 or Type 2 diabetes

- Pain attributed to symmetrical lower extremity diabetic peripheral neuropathy for at least 6 months

- DPN pain over the preceding 24 hours is =4 and <9 based on the 11-point NPRS (0-10)

- 22 to 80 years of age

- On stable diabetes treatment

- HbA1c less than or equal to 10%

- No recent changes to analgesic prescriptions

- ABI of =0.8 to =1.3

- Walks independently

- Willing and able to give consent

- If female, must be post-menopausal, surgically sterile, abstinent or practicing an effective method of birth control

- Can access an internet browser or smart phone

To be randomized after the 14-day run-in period, average pain (NPRS) must be = 4 and < 9 over preceding 7 days and subject must be 70% compliant with ePRO assessments (electronic diary)

Exclusion Criteria:

- Active, open ulcer on either extremity

- Significant peripheral vascular disease

- Venous insufficiency

- History of solid organ transplant or severe renal disease

- Diagnosed with a non-diabetic cause of chronic neuropathy

- Previous or current history of primary or tertiary hyperparathyroidism, hypercalcemia, psychiatric disorder, alcohol dependency, Hepatitis B or C, or HIV infection

- Significant cardiovascular disease

- Uncontrolled medical illness

- Requires or anticipates the need for surgery during the study

- Total foot depth of >8 cm

- Has received any investigational drug or device within 30 days

- Has used systemic corticosteroids within 3 months

- History of malignancy within 5 years in treatment area

- A psychiatric disorder of sufficient severity

- Receiving prn narcotic medications

- History of drug or alcohol abuse within 1 year

- Implanted pacemaker, defibrillator, neurostimulator, spinal cord stimulator, bone stimulator, cochlear implant, or other implanted device with an implanted metal lead(s0

- Pregnant or planning to become pregnant

- Previous treatment with Provant Therapy

- Unwilling to follow instructions or comply with study instructions

- Pain from any other source that could confuse DPN pain assessment

- Clinically significant foot deformity

- Skin condition that could alter peripheral sensations

- Previous surgery to the spine or lower extremity with residual symptoms of pain or difficulty with movement.

- Clinically significant arthropathy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Active Provant Therapy System
Treatment with active Provant Therapy System
Inactive (sham) Provant Therapy System
Treatment with inactive Provant Therapy System

Locations

Country Name City State
United States River Birch Research Alliance, LLC Blue Ridge Georgia
United States Wake Family Medicine, PC Cary North Carolina
United States Mountain View Clinical Research Denver Colorado
United States Lake Internal Medicine Associates Eustis Florida
United States MediSphere Medical Research Center, LLC Evansville Indiana
United States Clinical Physiology Associates Fort Myers Florida
United States Healthcare Research Network Hazelwood Missouri
United States The Center for Pharmaceutical Research, LLC Kansas City Missouri
United States Palm Research Center Las Vegas Nevada
United States Physician's Research Group Mesa Arizona
United States Spotlight Research Center Miami Florida
United States Valley Clinical Research Northridge California
United States Rainier Clinical Research Renton Washington
United States Northern California Research Sacramento California
United States Diabetes Research Center Tustin California
United States Great Lakes Medical Resarch Westfield New York
United States Heartland Research Associate, LLC Wichita Kansas
United States Clinical Research of Central Florida Winter Haven Florida

Sponsors (1)

Lead Sponsor Collaborator
Regenesis Biomedical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory Endpoint: Changes in the Work Productivity and Activity Impairment Questionnaire (WPAIQ) (Questions 2-4) The Work Productivity and Activity Impairment Questionnaire (WPAIQ) is a validated 6 question assessment tool that measures time missed from work, impairment of work and regular activities due to their health problem. Subjects are asked if they are working (Question 1), and if answer is yes, subjects are asked about the effect their diabetic neuropathy (DN) has on their ability to work and perform regular activities in the past 7 days.
Mean change from Baseline to 4-months are displayed below (Questions 2-4) for subjects that responded "Yes" to working in Question 1. Questions 2-4 are answered in number of hours.
Baseline to 4 Months
Other Exploratory Endpoint: Changes in Intraepidermal Nerve Fiber Density (IENFD) at the Distal Thigh and Distal Leg - Part A Optional two 3 mm punch skin biopsies will be performed at baseline and end of treatment to assess IENFD. At the Enrollment Visit, one biopsy will be obtained at the distal leg, 10 cm above the lateral malleolus on the right leg and a second biopsy will be obtained at the distal thigh, 10 cm above the superior margin of the patella on the lateral right leg. At the end of Part A study visit Month 4 (Day 121), a second set of biopsies will be obtained lateral to the baseline biopsies and shipped overnight to the central lab.
For Active Group and Sham Group displayed below, result are the change in nerve fiber density from Baseline to Month 4.
Baseline to Month 4
Other Exploratory Endpoint: Change in Pain Intensity During Part B Absolute change in pain intensity as measured by the 11-point, numerical pain rating scale (NPRS) (0-10; where 0=no pain, to 10=worst possible pain). Results below display the change from Baseline to Month 12 for subjects that participated in the open-label extension (Part B), stratified by their original randomization in Part A. Baseline through 12 months
Other Exploratory Endpoint: Changes in Nerve Conduction Studies of Velocity During Part B Using the NC-stat DPNCheck, the sural nerve conduction velocity was recorded on the right and left legs. An increase in velocity would suggest DPN improvement. Results below display the mean change in velocity and from Baseline to Month 12 for subjects that participated in the open-label extension (Part B), stratified by their original randomization in Part A. Baseline to Month 12
Other Exploratory Endpoint: Change in Neuropathy Related Quality of Life (NeuroQoL) During Part B A validated set of health-related quality of life measures that are domain specific.Subjects will completed 6 domains: (1)Pain, (2)Lost/Reduced Feeling, (3)Diffuse Sensory Motor Symptoms, (4)Restrictions in Activities of Daily Living, (5)Disruptions in Social Relationships, and (6)Emotional Distress.The short forms were completed by the subject at the Enrollment Visit, end of study visit (Day 121) and at 12 months. Each question in the domain was rated on a symptom scale from 1 (never) to 5 (all the time) and a bothersome scale from 1 (none) to 3 (very much).
The total score for the domain was calculated by multiplying the symptom score by the bothersome score. The scale range is from 1 to 15 where the minimum (best/least symptomatic) score is 1 and the maximum (worst/most symptomatic) score is 15.
Results below display the change from Baseline to Month 12 for subjects that participated in the open-label extension (Part B), stratified by their original randomization in Part
Baseline to Month 12
Other Exploratory Endpoint: Changes in Nerve Conduction Studies of Amplitude During Part B Using the NC-stat DPNCheck, the sural nerve conduction amplitude was recorded on the right and left legs. An increase in amplitude would suggest DPN improvement. Results below display the mean change in amplitude from Baseline to Month 12 for subjects that participated in the open-label extension (Part B), stratified by their original randomization in Part A. Baseline to Month 12
Other Exploratory Endpoint: Changes in the Work Productivity and Activity Impairment Questionnaire (WPAIQ) (Questions 5-6) The Work Productivity and Activity Impairment Questionnaire (WPAIQ) is a validated 6 question assessment tool that measures time missed from work, impairment of work and regular activities due to their health problem. Subjects are asked if they are working (Question 1), and if answer is yes, subjects are asked about the effect their diabetic neuropathy (DN) has on their ability to work and perform regular activities in the past 7 days.
Mean change from Baseline to 4-months displayed below (Questions 5-6) for subjects that responded "Yes" to working in Question 1. Questions 5 and 6 use a 0-10 scale where 0 = no effect on work and/or daily activities and 10 =DN completely prevented me from working and/or doing daily activities.
Baseline to 4 Months
Other Exploratory Endpoint: Changes in Intraepidermal Nerve Fiber Density (IENFD) at the Distal Thigh and Distal Leg - Part B Optional two 3 mm punch skin biopsies will be performed at baseline and end of treatment to assess IENFD. At the Enrollment Visit, one biopsy will be obtained at the distal leg, 10 cm above the lateral malleolus on the right leg and a second biopsy will be obtained at the distal thigh, 10 cm above the superior margin of the patella on the lateral right leg. At the end of Part A study visit Month 4 (Day 121), a second set of biopsies will be obtained lateral to the baseline biopsies and shipped overnight to the central lab. At the end of Part B study visit Month 12 (Day 361), a final set of biopsies will be obtained lateral to the Month 4 biopsies.
Results displayed are the change in nerve fiber density from Baseline to Month 12 for subjects that participated in the open-label extension (Part B), stratified by their original randomization in Part A.
Baseline to Month 12
Primary Change in Pain Intensity Absolute change in pain intensity as measured by the 11-point, numerical pain rating scale (NPRS) (0-10; where 0=no pain, to 10=worst possible pain). Baseline through 4 months
Secondary Patients With 2 Point or 30% Reduction in Pain at 4 Months Percentage of patients who have either a 2 point or 30% reduction in (pain) NPRS at 4 Months.
Absolute change in pain intensity as measured by the 11-point, numerical pain rating scale (NPRS) (0-10; where 0=no pain, to 10=worst possible pain).
Baseline to 4 months
Secondary Patient Global Impression at 4 Months Patient Global Impression at 4 Months. The question assesses change since the start of the study on a 7-point scale ("Since the start of the study, how has your diabetic neuropathy in your legs changed?"), and to score it as either very much worse, much worse, minimally worse, no change, minimally improved, much improved or very much improved. Baseline through 4 months.
Secondary Time to 30% or 2-point Reduction in NPRS, Whichever Comes First, Through 4 Months Absolute change in pain intensity as measured by the 11-point, numerical pain rating scale (NPRS) (0-10; where 0=no pain, to 10=worst possible pain). Number of participants achieving a 30% or 2-point reduction at or prior to weeks 1, 4, 8, 12 and 17 are displayed below. Through 4 months
Secondary Change in Neuropathy Related Quality of Life (NeuroQoL) Between Baseline and End of Treatment at 4 Months. A validated set of health-related quality of life measures that are domain specific.Subjects will completed 6 domains: (1) Pain, (2) Lost/Reduced Feeling, (3) Diffuse Sensory Motor Symptoms, (4) Restrictions in Activities of Daily Living, (5) Disruptions in Social Relationships, and (6) Emotional Distress.The short forms were completed by the subject at the Enrollment Visit and end of study visit (Day 121). Each question in the domain was rated on a symptom scale from 1 (never) to 5 (all the time) and a bothersome scale from 1 (none) to 3 (very much).
The total score for the domain was calculated by multiplying the symptom score by the bothersome score. The scale range is from 1 to 15 where the minimum (best/least symptomatic) score is 1 and the maximum (worst/most symptomatic) score is 15. The mean change from Baseline to month 4 is displayed below.
Baseline to 4 months
Secondary Change is Skin Perfusion Pressure (SPP) for Baseline to End of Treatment at 4 Months SPP was measured at two locations on each foot (dorsal right and left and plantar right and left). Mean change displayed from Baseline to 4-months displayed below.
SPP measures pressure in mmHg; an increase in pressure is favorable.
Normal SPP: 50 mmHg to 100 mmHg
Marginal Ischemia SPP: 30 mmHg to 50 mmHg
Critical Limb Ischemia / PAD SPP: < 30 mmHg
Baseline to 4 months
Secondary Changes in Nerve Conduction Studies of Velocity Between Baseline and End of Treatment at 4 Months. Using the NC-stat DPNCheck, the sural nerve conduction velocity was recorded on the right and left legs. An increase in velocity would suggest DPN improvement. The mean change from Baseline to 4-months is displayed below. Baseline to 4 Months
Secondary Changes in Quantitative Sensory Testing (QST) Between Baseline and End of Treatment at 4 Months. Contact thermal stimulation will be delivered using the Medoc Ltd. Q-Sense system to assess cool sensation threshold, warm sensation threshold and heat pain threshold modalities using the method of limits. Within the cool and warm sensation modalities, the trial is repeated 4 times on each foot and 3 times on each foot for heat pain threshold modality. The cool thermal testing will be conducted prior to the warm and heat pain thermal testing.
Mean change from baseline to 4-months displayed below.
Baseline to 4 months
Secondary Changes in Nerve Conduction Studies of Amplitude Between Baseline and End of Treatment at 4 Months. Using the NC-stat DPNCheck, the sural nerve conduction amplitude was recorded on the right and left legs. An increase in amplitude would suggest DPN improvement. The mean change from Baseline to 4-months is displayed below. Baseline to 4 Months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05558878 - Effect of Ambroxol in Diabetic Peripheral Neuropathy N/A
Completed NCT03676595 - Video Game Balance Training for Patients With Diabetic Neuropathy N/A
Completed NCT03440203 - Prevalence of Peripheral Neuropathy and Its Impact on Activities of Daily Living in Patients With Type 2 Diabetes
Recruiting NCT03725917 - Patients With Diabetic Neuropathy Who Receive Physiotherapy Treatment Will Have a Decrease in Diabetic Foot Ulcers N/A
Enrolling by invitation NCT03907189 - Ambulation as a Factor on Oscillating Thermometry
Completed NCT03888872 - Effect of High Tone Power Therapy on Neurophysiological Measures and Function Outcome in Patients With Diabetic Neuropathy N/A
Withdrawn NCT03354806 - Peripheral Analgesia in Painful Diabetic Neuropathy N/A
Enrolling by invitation NCT05921097 - Comparison of Histamine and Local Heating for Evoking the Axon-reflex Flare Response in Diabetes
Active, not recruiting NCT06463015 - Posterior Tibial Nerve PRF for Diabetic Neuropathic Pain N/A
Completed NCT05299918 - Diabetic Neuropathy Rapid Screening Test in Turkish Patients With Type 2 Diabetes: Sudoscan
Not yet recruiting NCT06201611 - Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy. Phase 2/Phase 3
Suspended NCT03685253 - Nicotinamide Riboside for Diabetic Neuropathy Phase 1/Phase 2
Completed NCT05977465 - Empagliflozin in Treatment of Peripheral Diabetic Neuropathy Phase 1/Phase 2
Completed NCT03847779 - Microcirculatory Vasomotor Changes in Type 2 Diabetes With Peripheral Neuropathy N/A
Recruiting NCT05642143 - Deep Phenotyping of Bone Disease in Type 2 Diabetes and Relations to Diabetic Neuropathy
Terminated NCT04253860 - Effect of Transcutaneous Electrical Nerve Stimulation in Diabetic Neuropathy Phase 3
Completed NCT03988413 - Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People Phase 1
Not yet recruiting NCT05461274 - Determining Patterns In Trial Experiences of Diabetic Neuropathy Patients
Recruiting NCT04841720 - A Study Evaluating Drug-Drug Interaction (DDI) Between HSK16149 Capsules and Metformin Hydrochloride Tablets Phase 1